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ABSTRACT  
Inflammation contributes to vascular disease progression. However, the role of 
circulating inflammatory molecules on microvascular endothelial cell (mECs) is not fully 
elucidated. The aim of this study was to investigate the effects of the short pentraxin 
CRP on microvascular endothelial cell angiogenic function. Subcutaneously implanted 
collagen plugs seeded with human mECs exposed to monomeric CRP (mCRP) in mice 
showed formation of an extended network of microvessels both in the plug and the 
overlyning skin tissue,  while mECs exposure to pentameric native CRP (nCRP) induced 
a much milder effect. To understand the mechanisms behind this angiogenic effects, 
mECs were exposed to both CRP forms and cell migration, wound repair and tube-like 
formation were investigated. nCRP effects were moderate and of slow-onset whereas 
mCRP induced rapid, and highly significant effects. We investigated how circulating 
nCRP is transformed into mCRP by confocal microscopy and western blot. nCRP is 
transformed into mCRP on the mECs membranes in a time dependent fashion. This 
transformation is specific and in part receptor dependent, and the formed mCRP triggers 
F3 gene transcription and TF-protein expression in mECs to induce angiogenesis. F3-
silenced mECs are unable to form angiotubes. In agreement, mCRP induced 
upregulation of the TF signaling pathway in mECs with downstream phosphorylation 
of AKT and activation of the transcription factor ETS1 leading to increased CCL2 release. 
The circulating pentraxin nCRP with little pro-angiogenic effect when dissociated into 
mCRP on the surface of mECs is able to trigger potent proangiogenic effects by inducing 
F3-gene upregulation and TF signaling.  
Keywords: tissue factor, angiogenesis, vessel wall remodeling, C-reactive protein, 
endothelial cells.  
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Abbreviations: 
nCRP: pentameric C-reactive protein form   
mCRP: monomeric C-reactive protein form 
HMEC-1: Human microvascular endothelial cells 
F3: Tissue factor gen 
TF: Tissue factor 
VSMC: Vascular smooth muscle cells 
BAEC: Bovine aortic endothelial cells  
mECs: microvascular endothelial cells 
siRNA: Silencing RNA  
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INTRODUCTION 
C-reactive protein (CRP) is a member of the pentraxin family secreted by the liver and 
found in the circulation as a pentamer formed by five identical, non-covalently 
associated 23 kDa monomers (1). Increased CRP levels are associated with increasing 
risk of cardiovascular events(2, 3). 
 
Circulating pentameric CRP (native CRP (nCRP)) can undergo dissociation into its 
monomeric form (mCRP), which has different biological properties from those of nCRP. 
mCRP is localized in fibrous tissues of normal blood vessel intima (4), in inflamed 
tissues (5) and it accumulates in human atherosclerotic lesions (6) where it colocalizes 
with macrophages (7) and vascular smooth muscle cells (VSMC) (8). Our group 
reported that local synthesis of CRP could contribute to carotid plaque 
neovascularization and to an increased risk of atherosclerotic plaque hemorrhagic 
transformation(6), even contributing to the likelihood of atherosclerotic plaque 
rupture(9). Angiogenic function evaluated in vitro with bovine aortic endothelial cells 
(BAECs) indicated that mCRP could be a potent inducer of angiotube formation(10). 
However a mechanistic analysis on how the inflammatory pentraxins induce 
angiogenesis was still missing.  
 
In vivo angiogenesis is predominantly mediated by microvascular endothelial cells 
(mECs) sprouting from preexisting vessels, leading primarily to new capillaries (11). 
Angiogenesis and also inflammation appear to play a role in the process of plaque 
instability and plaque disruption. Angiogenesis is often found in the early vessel wall 
remodeling, and it favors leukocyte and macrophage infiltration in growing 
atherosclerotic lesions. Previous studies have reported that microvessel density was 
increased in coronary plaques prone to rupture (AHA-classification coronary type VI 
plaques) (12) and in ruptured and lipid-rich plaques when compared with fibrocalcific 
lesions (13). 
 
Endothelial cells have a heterogeneous phenotype. Indeed, large vessel luminal ECs in 
direct contact with circulating blood, such as the ECs in the coronary arteries, do not 
express tissue factor (TF), whereas vasa vasorum in normal plaques and intraplaque 
mECs show endogenous TF expression(14). TF is a multifunctional signaling receptor 
involved in blood coagulation and in intraluminal arterial thrombosis triggered when  
inflammatory plaque content is exposed to circulating blood(15, 16). Beyond its 
thrombotic effects TF is involved in cell signaling(14, 17, 18). 
 
We previously reported that mCRP, but not native pentameric CRP, significantly 
enhanced platelet activation, adhesion, and thrombus growth under arterial flow 
conditions (19). Further, we have recently shown that mCRP generated by the 
dissociation of nCRP on the surface of platelets attached to collagen (20) or to purified 
biological substrates has immediate prothrombotic effects(21). 
 
Here our objective was to identify the mechanisms behind the angiogenic effect of 
CRP. We report that a) mECs promote CRP dissociation into mCRP; and, b) operative 
intracellular TF-signaling is required to induce the pro-angiogenic mCRP effects in 
mECs.  
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MATERIAL AND METHODS 
CRP isoforms obtention 
High purity human native CRP (Calbiochem) was stored in 10 mmol/L Tris, 140 mmol/L 
NaCl buffer (pH 8.0) containing 2 mmol/L CaCl2 to prevent spontaneous formation of 
mCRP. mCRP was obtained by urea chelation from purified human CRP as previously 
described in the same low ionic strength buffer (19, 22). CRP preparations were 
processed and tested to avoid contaminants; as such, preparations were dialyzed in 
large Tris-HCl buffer volumes to fully remove sodium and endotoxin levels were below 
the detection limit of the limulus assay. 
Blood collection  
Freshly drawn venous blood from non-smoking healthy volunteers with informed 
consent was collected in 10 UI/mL sodium heparin. Blood samples were kept at room 
temperature, and used within 2 hours of collection. Donors claimed not to have taken 
any medication during 2 weeks prior to blood extraction. Procedures were approved by 
the Clinical Research Committee of the Hospital de la Santa Creu i Sant Pau. 
Cell culture 
Human microvascular endothelial cells (HMEC-1) were a kind gift from the Centre of 
Disease Control (Atlanta, GA).(23) mECs (HMEC-1) were cultured in MCDB131 media 
(Invitrogen) and supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine 
(Invitrogen) and 50 mg/mL gentamicin (Invitrogen) as previously reported (14, 18, 24).  
mECs were cultured in normoxic (21% O2) conditions in an incubator with standard gas 
mixture (74% N2 and 5% CO2). Additionally, mECs were cultured in hypoxic (1%O2) 
conditions in a Hipoxic/Anoxic Workstation:H35 (Don Whitley Scientific LTD.) with 94% 
N2 and 5% CO2.  
Angiogenesis assay in vivo 
All animal experiments were performed under approved protocols of the institutional 
animal use and care committee. Angiogenesis was investigated as previously 
described(14, 18, 25). Briefly, 1 x 107 mECs were suspended in 300 μl of Matrigel 
containing nCRP or mCRP (at 1, 3 or 10 μg/mL) and injected subcutaneously in nude 
mice. All mice were euthanized at seven days post-injection. Plugs and the surrounding 
skin were visualized macroscopically (Leica AF 6000LX Stereomicroscope with digital 
camera DFC, 8 bits of resolution, objective 1.0x0.03/1.0x0.09). Skin and plugs were 
fixed, embedded and stained with appropiate antibodies, or extracted for hemoglobin 
quantification. Negative control plugs contained only Matrigel. When indicated the 
experiment was performed with siRNA-random and siRNA-TF-mECs. 
Hemoglobin quantification 
Hemoglobin quantification was performed as previously described (26). Briefly, the 
Matrigel plugs were homogenized in 500 µl water on ice and cleared by centrifugation 
at 200g for 6 min at 4ºC. The supernatant was collected and used in triplicate to 
measure hemoglobin content with Drabkin’s reagent (Sigma-Aldrich) according to 
manufacturer instruction. The absorbance was measured at 540 nm. 
Angiotube formation in a 3D basement membrane 
Three-dimensional (3D) cultures were prepared on three-dimensional basement 
membrane (BD Matrigel™) (BD Biosciences) as described (18). Cells were cultured for 
different times. Control and treated mECs migration was investigated by real-time 
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acquisition of images at 30-minute intervals for 8 hours (Leica DMIRE2). Images of 5 
randomly selected areas of each plate were acquired, digitalized, and processed with 
Leica Software TCS-AOBS. The total tub length and the area covered by tubes from 3 
independent experiments were measured. 
Transwell migration assay 
Chemotaxis assays were carried out with Transwell chambers. mECs were plated into 
modified Boyden chambers (Corning Costar Corporation) as described (14). Briefly, 6.5 
nm transwell chambers with 8 μm pores (Corning) were coated with 10 μg/mL of type I 
collagen (Sigma) for 2 hours at 37º C.  5 x 104 cells/well were placed in the upper 
chamber and the lower chamber was filled with 500 μL of media containing nCRP (1, 3 
or 5 µg/mL) or mCRP (1, 3 or 5 µg/mL). After 4 hours at 37º C, cells that migrated to 
the bottom of the membrane were fixed and stained with Diff-Quick (VWR Scientific 
Products). The total number of migrated cells was determined by counting five fields in 
each well per experimental condition using a phase-contrast microscope 
(magnification, x20).  
Cell migration assay  
Cells were seeded in 35 mm glass bottom sterile culture dishes until reaching 
confluence. The confluent cell monolayer was wounded by manually scraping 
with a soft sterile 200 μL pipette tip to create a double-sided wound. Confluent 
cultures (after scapping) of mECs were incubated with mCRP (0, 3 and 5 µg/mL) 
and with nCRP (0, 3, 5 µg/mL). Cell migration and wound repair were analyzed 
over a period of 8 hours (37°C) with 10% FBS. Images were taken under a 10x 
lens, using an inverted microscope (Leica DMIRE2). The area free of cells in each 
field was calculated using ImageJ software, and values were averaged. 
Measurements were made at time 0 and during cell migration. Cell migration and 
wound repair were quantified by measuring the residual cell-denuded area. 
Quantization was done by measuring the distance to the wound edge of the 
migrating as previously reported (14). Values were expressed as a percentage of 
the cell-covered area at time 0 and at the time to wound closure, as previously 
reported (27). 
In a second approach, a multi-scratch wound-repair assay was performed.  mEC 
were seeded on 90 mm diameter dish grown in the presence of serum and grown 
to confluence. The medium was changed 16 h before wounding.  Confluent cells 
were injured with multiple parallel scratches by scraping with 0.1–2 μl tips 
across the dish (more than 50% of cells were detached from the dish).  Cells 
were incubated in the presence or absence of 3µg/mL mCRP. Cells were allowed 
to migrate repairing the wound for 4 hours and RNA and protein were isolated.  
The objective was to collect cells in migration and we produced scratches to 
have more than 60% of wounded area (28, 29).  
The experiments were performed in normoxic and hypoxic conditions.  
CRP dissociation assay 
Briefly, 2 x 105 mECs were seeded on 35 mm glass bottom sterile culture dishes. Cells 
were kept in MCDB131 supplemented with 10% FBS for 14 h. Cells were then 
incubated with nCRP (3 µg/mL) for 8 hours (37°C). The experiments were performed 
under normoxic and hypoxic conditions. Cells were processed for immunofluorescence, 
or extracted for protein and RNA analysis. 
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In order to study cell receptors involved in CRP dissociation, mECs were incubated for 
1 hour with blocking antibodies against CD32 (100 µg/mL) (AF1330 and AF1257 
respectively, R&D Systems). Then, cells were treated with nCRP (3 µg/mL) and 
incubated over a period of 8 hours (37°C). These experiments were performed under 
normoxic conditions. Cells were processed for immunofluorescence to detect mCRP 
expression on the cell membrane.  
Immunofluorescence staining 
Cells were rinsed with PBS pH 7.4 and fixed with 3.8% paraformaldehyde for 15 min. 
Fixed slides were washed with PBS and incubated in blocking buffer. Then, they were 
incubated in Signal Enhancer for 30 min and washed again. Immunodetection of CRP 
isoforms was performed with the monoclonal antibodies against nCRP (clone 1D6) and 
mCRP (clone 8C10), kindly provided by Dr LA Potempa. Cell nuclei were 
counterstained with Hoechst 33342.  
Five-micrometer-thick frozen Matrigel plug sections were prepared for immunostaining 
as described(30). Controls were stained with secondary antibodies only.  
Images were recorded by Leica inverted fluorescence confocal microscope (Leica TCS 
SP2-AOBS, Wetzlar, Germany) and coverslides were viewed with HCX PL APO 
20X/0.7 IMM Corr and HCX PL APO 63x/1.2 W Corr/ 0.17 CS objectives. Fluorescent 
images were acquired in a scan format of 1024 x 1024 pixels in a spatial data set (xyz 
or xzy) and were processed with the Leica Standard Software TCS-AOBS. Controls 
with no primary antibody and controls without cells showed no fluorescence labeling.  
Protein Isolation  
Briefly, supernatants were collected and cells were washed twice with PBS. Cells were 
scraped and stored frozen (-80 ºC) and supernatants were precipitated with acetone 
during at least 1 hour at -20ºC.  
Endothelial cells were sequentially extracted based on differential protein solubility 
(31). Tris-soluble (cytosolic) fraction and urea-detergent soluble 
(cytoskeleton/membrane) fractions were obtained. Sample contaminants (salts, lipids, 
etc.) of protein extracts from cells and supernatants were removed with a commercial 
kit (2D-CleanUp Kit, Amersham Biosciences, UK) and protein concentration was 
measured with 2D-Quant Kit (Amersham Biosciences, UK) as indicated by the 
manufacturer.  
Western Blot Analysis  
Cell supernatants and membranes (25 μg protein) were resolved by SDS-PAGE and 
electrotransferred to nitrocellulose membranes.
 
Detection was performed with: 
monoclonal antibodies against nCRP (clone 1D6) and mCRP (clone 8C10), rabbit TF 
antibody (American Diagnostica),  rabbit anti-phospho-Akt Ser473 antibody, rabbit anti-
Akt antibody (Cell Signaling), rabbit anti-phospho-Ets-1 Thr38 antibody (Novus 
Biological), and  mouse Ets-1 (1G11) (Abcam). Band densities were determined with 
the ChemiDoc™ XRS system (Bio-Rad) in chemiluminescence detection mode and 
analyzed with Quantity-One software (Bio-Rad).  
Real time PCR 
RNA from cell lysates extracted by RNeasy isolation kit (Qiagen) was reverse 
transcribed. mRNA levels were analyzed by real time PCR. Assays were used for TF 
(Hs00175225m1), and CD32 (Hs01634996_s1 and hCG1642498 (Thermo Fisher 
scientific) as described(14). Human GAPDH (4326317E) (Thermo Fisher scientific) was 
used as an endogenous control. Taqman real time PCR was performed as previously 
described(32). mRNA expression was quantified and normalized by GAPDH. 
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Silencing RNA (siRNA) 
F3 and CD32 silencing by siRNA were performed with a Nucleofector device and its 
corresponding kit (Amaxa, Inc.). The transfection protocol was performed following 
manufacturer’s instructions using the T16 program, as we have previously 
reported(14). The scrambled siRNA or annealed pre-designed siRNA against TF 
(s4932), and CD32 (s194408 and s5073) were purchased from Thermo Fisher 
scientific. In all experiments, a scrambled siRNA was used as control. 
 
Tissue Factor procoagulant activity 
Briefly, 200 x 103 cells were seeded on 35 sterile culture dishes with 500 μL of media 
containing nCRP (0, 1, 3 or 5 µg/mL) or mCRP (1, 3 or 5 µg/mL). After 2, 4, 6, 8, and 
24 hours cells supernatant was collected and tissue factor procoagulant activity (TF-
PCA) was measured by using a commercially available chromogenic FXa generation 
assay (Actichrome TF, American Diagnostic) following the manufacturer’s instructions. 
CRP proliferation assay  
To determine CRP dependent mECs proliferation cells were incubated with nCRP (0,1, 
3 or 5 µg/mL) or mCRP (1, 3 or 5 µg/mL). After 2, 4, 6, 8, and 24 hours cells were 
harvested, ethanol (70%) fixed overnight at -20ºC, stained with propidium iodide (50 
μg/mL) followed by flow cytometry analysis.  
Statistical analysis 
Results are expressed as mean ± SEM and tested for statistical significance by the 
two-tailed Student's t test or ANOVA, followed by the Dunnett’s test, to determine 
statistical significance between treatments. P<0.05 was considered statistically 
significant. 
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RESULTS 
Angiogenesis assay in vivo  
To investigate the in vivo effects of CRP we subcutaneously inoculated nude mice with 
mECs suspended in Matrigel. Three conditions were investigated: control cells, nCRP 
exposed (1, 3 and 10 µg/mL)-mECs and mCRP exposed (1, 3 and 10 µg/mL)-mECs. 
Angiogenesis, both in the Matrigel plug and in the overlying skin tissue, was evaluated 
after 7 days. nCRP at low concentrations (1 and 3 µg/mL) did not stimulate the 
formation of blood- filled microvessel (Fig 1A Matrigel plug; Fig  1B hemoglobin 
concentration). Only the highest nCRP concentration (10 µg/mL) induced the 
development of thin microvessels (P<0.01). mCRP induced a statistically significant 
formation of thin and long blood-filled microvessels from the lowest tested dose of  1 
µg/mL. Quantification of hemoglobin content in the retrieved plugs indicated competent 
neovessels (Fig 1B). mCRP-mECs plugs had a significantly increased blood-perfused 
neovessel network formed at all tested concentrations (P<0.01 at 1, and P<0.001 at 3 
and 10 g/mL). The statistical comparison between the two CRP forms demonstrated 
that the effect of mCRP was significantly higher at all concentrations (P<0.05 at 1 and 
3, and P<0.01 at 10 g/mL).  
 As shown in Figure 1A (bottom), the skins overlying the plugs were analyzed. There 
was little vascularization over plugs containing nCRP-mECs. Only the highest nCRP 
dose (10ug/ml) induced a mild but significant vascularization (p<0.05). Instead 
vascularization over mCRP-mECs plugs was highly significant (Figure 1C). These 
results indicate that mCRP is able to induce angiogenesis in vivo rapidly and efficiently. 
The mechanisms behind this significant in vivo pro-angiogenic effect of mCRP were 
further investigated in in vitro experiments.  
Endothelial tube formation assay 
To understand mCRP-induced angiogenesis we first tested mCRP effects in 3D-BM 
cultures (Fig 2A). Both CRP forms induced formation of angiotubes but with different 
patterns and density. The appearance and distribution of the angiotubes in mCRP 
treated mECs was very different from that obtained in untreated mECs or in mECs 
treated with nCRP (Fig 2A). mCRP induced newly formed tubes that connected in a 
very complex way to form fairly extensive networks while nCRP produced individual 
capillary-like tube formation. In fact, the quantification of the area covered by tubes 
revealed that mCRP, at any tested concentration, induced a significantly larger network 
of angiotubes than control cells (P<0.01 at 1 µg/mL and P<0.001 at 3 and 5 µg/mL) 
and nCRP-mECs (P<0.01 at 3 µg/mL and P<0.001 at 1 and 5 µg/mL) (Fig 2B-2C). 
Representative larger images of nCRP and mCRP-induced tube formation, shown in 
Figure 2D, evidence the different angiotube network density induced by the two CRP 
forms. 
Chemotaxis and wound healing assay  
In the chemotaxis assay, we observed that whereas nCRP did not induce mECs 
migration, mCRP significantly induced mEC motility, achieving a significant difference 
from controls at 3 µg/mL of mCRP (P<0.05) (Fig 3A). The difference between the two 
CRP forms was significant at all tested concentrations (P<0.05 at 1 µg/mL and P<0.001 
at 3 and 5 µg/mL).  
Wound-repair analysis indicated that the time to closure and the kinetics of cell repair 
were also differentially affected by both isoforms (Fig 3B-3C). Representative images 
of phase-contrast micrographs after 4 hours of incubation are shown in Figure 3B. The 
analysis of cell coverage rate (covered surface/time) during the first two hours of 
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incubation showed that both CRP forms induced a faster repair of the wounded area 
than untreated cells. However, mCRP induced a faster repair than nCRP (P<0.01 and 
P<0.001 at 3 and 5 µg/mL) (Fig 3C). Accordingly, time to wound closure was 
significantly shorter with mCRP (Fig 3D). The short time period in the migration assay 
(interval of 4 to 6 hours) is below cell doubling time and along with Boyden chamber 
results evidence that both CRP forms affect migration rather than proliferation.  
In a parallel experiment with multi-scratch wounding, to analyze the effect of hypoxia, 
we evidenced that mCRP (3 g/mL) also induced rapid repair (within 4 hours) in 
hypoxic conditions (Fig 3E).  
CRP induces tissue factor expression in mECs 
We had previously shown that in mECs autocrine TF-signaling induced migration and 
angiogenesis (18) . Indeed, upregulation of F3 transcription in migrating mECs was 
already detectable at 2 hours and peaked at 4 hours(18), times compatible with the 
functional changes evidenced by treating mECs with mCRP. Therefore we investigated 
whether the effects of mCRP on mECs-angiogenesis could be mediated by triggering 
F3 upregulation and TF-signaling. Real time PCR experiments showed that mECs 
treated with mCRP (3 µg/mL) for 4 hours significantly increased TF mRNA levels both 
in normoxic and hypoxic conditions (P<0.05) (Fig 4A; 4D). Interestingly TF mRNA 
levels were induced by mCRP but not by nCRP (3 µg/mL /4hours) (P<0.05) (Fig 4B; 
4E). Accordingly, TF protein levels expressed on mECs cells were significantly 
increased only after mCRP treatment (P<0.05) (Fig 4C; 4F). We had previously shown 
that autocrine TF-signaling in mECs induced phosphorylation of Akt and Ets and 
upregulation of CCL2 expression. Accordingly mCRP 3µg/ml treated mECs, after 0, 2, 
4, 6, 8 h of culture showed upregulation of phospho-Akt and of phospho-Ets-1 (Fig 4G). 
The release of CCL2, marker of TF-induced mEC-angiogenesis(18), was significantly 
increased in mCRP exposed microvascular endothelial cells (Figure 4H).  
 mCRP, TF and mECs migration 
To determine whether upregulation of F3 transcription and TF protein signaling 
mediated CRP- induced migration, the F3 gene was silenced in mECs and migration 
analyzed as described above by wound-repair analysis. Silencing of the F3 gene by 
siRNA-TF in mECs induced a reduction of 88+-2.5% in mRNA transcripts and 
disappearance of the TF-protein band (tested by western blot), as previously reported. 
Apoptosis in response to TF silencing was investigated by TUNEL and there were 
negligible levels of TUNEL-positive cells after silencing (3+-1% in scrambled siRNA 
treated cells and 2+-1% in siRNA-TF treated cells), similarly to what we have 
previously shown (14, 18).  
Migration was analyzed as described above and the area under curve (AUC) after 6 
hours showed that mCRP treated cells repaired the wound at a significantly faster rate 
than the controls (scrambled-siRNA-mECs) in normoxic and hypoxic conditions 
(P<0.001 and P<0.05 respectively) (Fig 5A-B). The cell growth kinetics (measured by 
cell covered area) evidenced that mECs exposed to mCRP migrated faster from the 
beginning (Suppl. Fig I). Silencing TF abrogated the effects of CRP on mEC-migratory 
function, in both normoxia and hypoxia (Fig 5A-B). The evaluation of time to wound 
closure (TWC) similarly showed that silencing-TF prolonged TWC. All together these 
results indicate that the effects of CRP on migration are mediated by F3 gene 
expression (Fig 5C-D). 
mCRP and mECs procoagulant activity 
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We determine the procoagulant effect of nCRP and mCRP on mECs (Suppl. Fig 
I). The cell supernatant exhibited increased procoagulant activity (PCA) only in 
incubations at the highest nCRP concentration (5µg/mL), PCA was increased in a 
time-dependent fashion reaching significance at 6 hours (P<0.05). On the 
contrary, PCA of mECs exposed to mCRP was increased in a concentration and 
time-dependent fashion at all concentrations (1, 3, and 5 µg/ml) from 2 hours 
until 8 hours. At 24 hours mECs  procoagulant activity (nCRP and mCRP 
exposed cells) were at levels of the control cells. 
mCRP and mECs-proliferation 
We evaluated the modifications in the cell cycle induced by nCRP and mCRP (1, 
3, and 5µg/mL) in a time dependent fashion. Cell cycle analysis by flow 
cytometry did not show significant differences in the expression patterns 
between CRP forms, concentrations, or incubation times (Suppl. Fig II).  
mCRP, TF and angiogenesis 
In vivo angiogenesis was tested as above, by subcutaneously inoculating nude mice 
with matrigel containing F3-silenced-mECs or with random-siRNA- controls, with and 
without mCRP (3µg/mL) (Fig 5E). mCRP induced angiogenesis in F3-expressing cells 
but could not induce angiogenesis in F3 silenced cells. Additionally, mCRP did not 
rescue angiotube formation in TF silenced mECS. Quantification of hemoglobin content 
showed that competent neovessel formation was not induced when F3 was silenced in 
mECs (Fig 5F).  
All together these results suggest that functional tissue factor gene expression is 
required for mCRP-induced pro-angiogenic effects in vivo as well as previously seen in 
vitro. 
CRP is dissociated by mECs-membranes 
nCRP showed the potential to induce migration but at a delayed time with respect to 
mCRP (Suppl.  Fig III). Therefore, we investigated whether nCRP undergoes 
dissociation into mCRP by interacting with mECs and then triggering neovessel 
formation.  
mECs were exposed to nCRP, afterwards supernatants were removed and cell 
membranes were blotted with antibodies against nCRP and mCRP. Whereas nCRP 
was reduced (and almost disappeared from mECs membranes) in a time-dependent 
fashion (Fig 6A), mCRP (absent up to 2hours) appeared on the mECs membrane in a 
time-dependant fashion. The cells and supernatants collected at 2-hours intervals for 
up to 8 hours confirmed the confocal microscopy observations. Whereas nCRP on 
supernatants were slowly disappearing with prolonged incubation time, reaching a 
statistically significant reduction after 6 hours (p<0.05) (Fig 6B), mCRP was 
increasingly appearing with prolonged incubation time in the cell membrane (P<0.05) 
(Fig 6C). Similar results were obtained when cells were cultured under hypoxic 
conditions (Suppl. Fig IV). 
mCRP dissociation on the mECs membranes was found partially dependent on CD32.  
Pre-incubation of mECs with CD32 blocking antibodies significantly reduced nCRP to 
mCRP transformation as seen by confocal microscopy (Fig 6D). The computer assisted 
morphometric image analysis indicated that blocking CD32 significantly reduced nCRP 
to mCRP transformation (P<0.01) (Fig 6E). In fact at long incubation times (from 4 to 8 
hours) monomerization into mCRP was abrogated in mECs without available 
membrane CD32 receptor (Fig 6D). The same results were obtained when CD32 was 
silenced (Fig 6D-6F). 
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DISCUSSION 
Inflammation plays a crucial role in atherosclerosis (33), and it has been associated to 
exacerbated angiogenesis although the mechanisms are not known (34-36). 
Inflammation might specifically exert distinct effects on the microcirculation of different 
target organs affecting their function when acute phase proteins, as CRP are released 
to plasma from the liver (1). 
CRP seems to be not only a predictive biomarker but also a causal factor on 
cardiovascular disease progression (37). As an effector molecule, growing data 
suggests that CRP may directly contribute to endothelial dysfunction (38). However, 
the mechanism by which CRP may affect angiogenic function has not been elucidated. 
In addition, we are starting to evidence that the pentameric liver-released form and the 
monomeric CRP form have different effects. In the present study we demonstrate that 
mCRP exerts potent angiogenic effects on microvascular endothelial cells.  We also 
describe a link between mCRP and procoagulant activity. In addition we report for 
the first time that CRP dissociates into mCRP on the endothelial cell membrane and 
that the mCRP induces angiogenic effects by upregulation of F3 gene transcription and 
TF signaling.  
Endothelial cells could be directly activated by mCRP through its interaction with 
lipid raft microdomains to mediate pro-inflammatory cellular responses (39) . 
mCRP is the bioactive conformational form triggering proinflammatory effects on 
the endothelium(40, 41). Growing evidence indicated that generation of mCRP 
can occur spontaneously by oxidative stress, low pH, and bioactive lipids from 
activated or damaged cells, but it can be accelerated in vivo under pathological 
conditions by bioactive lipids such as lysophosphatidylcholine exposed on the 
surface of activated or damaged cells.  Previous studies described the effect of 
native CRP on endothelial cells with no detectable changes before 4 hours (38, 
42, 43). The CRP induction became detectable only after 6 to 12 hours of 
incubation, reaching maximal effects at 24 hours coinciding with in vitro kinetics 
of dissociation into subunits(44). Our study shows that nCRP can induce TF 
expression after a 4-hour incubation period. In human phagocytes and in 
endothelial cells, native CRP binds primarily to Fcγ receptor IIa (CD32) and to 
some extent to FcγRI (CD64) (41, 45). It has been reported that CRP increases 
endothelial expression of CD32 in human and bovine aortic endothelial cells 
(HAECs and BAECs) (41, 46), and that CD32 can contribute to the proatherogenic 
effects of CRP (47). In mECs the expression of CD64 is very low (data not 
shown), therefore we studied the relative role of CD32 in CRP-monomerization. 
We demonstrate that mCRP transformation was abolished when CD32 Fcgamma 
receptor was blocked (by siRNA or by a specific antibody) in the microvascular 
endothelial cells. We found a significantly reduced CRP monomerization 
indicating a receptor-regulated process. In platelets we previously showed that 
the receptor involved in CRP monomerization was the heterodimer GPIIb-IIIa 
(21).This mechanism should occur mainly in loci with chronic or persistent 
inflammation (e.g., atherosclerotic lesions), where CRP is significantly up-
regulated and interaction with microvascular endothelial cells is increased.  
We hypothesized that the pro-angiogenic effects of mCRP in mECs were dependent on 
an operative F3 gene. TF the protein encoded by the F3 gene is a transmembrane 
signaling receptor expressed in ECs(48) and involved in  inflammation (18) and 
angiogenesis (49) being a central player in arterial wall remodeling (25). Previous 
studies showed that in mECs autocrine TF signaling (14) as well as monocyte-derived 
Wnt-5 (50) contributes to neovessel formation. The maturation of the newly formed 
microvessels was facilitated by TF- induced CCL2 secretion that recruited HVSMCs 
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toward ECs (14). This mature neovessel formation via CCL2 expression and release 
was mediated by transcription factor Ets-1 upregulation and activation(18).  Wu et 
al(51) observed TF expression in carotids of CRP-transgenic mice, associated the 
protein to vascular smooth muscle cells and concluded that TF expression is triggered 
by native CRP-induced ROS generation and Cirillo et al (52) reported native CRP-
induced proliferative effects on the vessel wall, both ECs and VSMCs. Here we are 
specifically studying mCRP-effects on microvascular endothelial cells and have 
identified that only mCRP is able to induce F3 upregulation and to significantly elevate 
TF protein levels in mECs. We also provide evidence  that mCRP are associated 
with an increased pro-coagulant activity in the microvascular endothelial cells 
secretome. The pro-angiogenic effects of mCRP are abrogated by F3 gene silencing, 
clearly showing the importance of TF in the process. Finally, mCRP induces pAKT, 
pETS1 and CCL2 secretion, following the pattern of activation of TF-induced signaling. 
Therefore, activation of the axis F3-TF-ETS1-CCL2 is required for the pro-angiogenic 
function of mCRP.   
Conclusion 
 In conclusion, our data show that in microvascular endothelial cells mCRP induces 
angiogenesis in vivo and promotes migration, wound repair and tube-like formation. 
The circulating CRP pentameric form that circulates in blood after its secretion by the 
liver can be dissociated into monomers on the surface of microvascvular endothelial 
cells partially via the Fc receptor CD32 and once monomerized CRP triggers 
angiogenic effects by inducing TF-signaling.  
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FIGURE LEGENDS 
Figure 1: Effect of CRP in angiogenesis assay in vivo. Blood vessels formed in 
Matrigel- plugs an skin tissue in vivo. Seven days after implantation the tumor and the 
surrounding skin were removed. (A) Top: Control human mECs and mECs treated with 
1, 3 or 10 µg/mL of either nCRP or mCRP. Scale bar: 5 µm. Bottom: A macroscopic 
view of representative skin tissue 7 days after injection of Matrigel plugs. Scale bar: 1 
mm. Images are representative from 3 animals for each group. (B) Colorimetric 
determination of hemoglobin concentration in Matrigel plugs. Seven days after 
implantation, plugs were removed and hemoglobin content analyzed. (C) Quantification 
of tube % covered area. Bars represent the mean ± SEM (N=3). Statistical analysis 
was performed by ANOVA followed by the Dunnett’s test to determine statistical 
significance between doses and Student's t test between treatments (*P< 0.05, **P < 
0.01 and ***P < 0.001 vs control).  
Figure 2:  mCRP induces microvessel formation in mECs. (A) Phase-contrast 
micrographs showing the morphology of human mECs treated with different 
concentrations of nCRP or mCRP for 8 hours in 3DBM culture Original magnification 
x10 (N=3). Scale bar: 100 µm. (B) The area covered by tubes and (C) average of total 
tube length were measured. Three independent experiments were run with each plate 
being measured at 5 randomly selected areas. Values are mean ± SEM. Statistical 
analysis was performed by ANOVA followed by the Dunnett’s test (*P<0.05, **P<0.01 
and ***P<0.001 vs control). (D) 3 µg/mL of nCRP or mCRP for 8 hours hours in 3DBM 
culture. Original magnification x10 (N=3). Scale bar: 100 µm.  
Figure 3: Effect of CRP in mEC migration. (A) Chemotaxis assay in Boyden 
chamber. Bars represent the mean ± SEM (N=3). Statistical analysis was performed by 
ANOVA followed by the Dunnett’s test (*P<0.05, **P<0.01 and ***P<0.001 vs nCRP or 
control). (B) Phase-contrast micrographs showing the wounded area covered by mECs 
treated with different concentrations of nCRP or mCRP after 4 hours of incubation. 
Original magnification x10 (N=3). Scale bar: 100 µm. (C-D) Migration wound-repair 
assay. Growth kinetics measured by (C) the velocity of coverage during 2 hours of 
incubation (cell covered area (%) / Time (h)) and (D) the time to wound closure (N=4). 
Statistical analysis was performed by ANOVA and Student's t test between treatments 
(*P< 0.05, **P < 0.01 and ***P < 0.001 vs ctrl).  (E) Migration assay after multi-scratch 
wounding. Confluent cultures were wounded by a multi-scratch procedure and 
incubated for 4 hours in the presence or absence of 3 µg/mL mCRP. Experiments were 
performed in normoxic and hypoxic conditions. Results are expressed as cells 
coverage area (%) relative to initial point. (N=4). Statistical analysis was performed by 
Student’s t-test (***P<0.001 vs control).  
Figure 4: CRP induces F3 transcription and TF signaling in human microvascular 
endothelial cells. mECs were incubated with nCRP (3 µg/mL) or mCRP (3 µg/mL) in 
(A-B-C) normoxic and (D-E-F) hypoxic conditions. In A-D, F3 transcript levels were 
measured in mECs before and after 4 hours of incubation with mCRP In B-E, F3 
transcription regulation by nCRP and mCRP. Results are expressed as relative (mean± 
sem; N=4).  (C; F) TF protein levels by Western blot at 4 hours normalized by β-actin 
(control ± sem; N=3). Statistical analysis was performed (A; D) by Student’s t-test and 
(B-C; E-F) by ANOVA test (*P<0.05 vs ctrl or time 0). (G) Western blots of mCRP 
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3µg/ml treated HMEC-1 after 0, 2, 4, 6, 8 h of culture. Western blots show phospho-
Ets, Ets protein, phospho-Akt and the Akt protein. To test for the equal loading, western 
blots were reprobed for β-actin. n = 4. (H) Concentration of CCL2 in the supernatants 
of endothelial cells incubated with mCRP (3µg/ml).  
Figure 5: Tissue factor (TF) is required for CRP pro-angiogenic effects in human 
microvascular endothelial cells (mECs). Confluent cultures of HMEC-1 or HMEC-1 
F3-siRNA monolayers were wounded by scraping and incubated with nCRP (3 µg/mL) 
or mCRP (3 µg/mL) in (A; C) normoxic and (B; D) hypoxic conditions. Growth kinetics 
(A-B) by area under the curve of the cell covered area relative to initial point after 6 
hours and (C-D) by the time to wound closure. (N=3). Statistical analysis was 
performed by ANOVA followed by the Dunnett’s test (*P<0.05; **P<0.01 and 
***P<0.001 vs scr-siRNA). (E) Blood vessels formed in Matrigel plugs in vivo. 
Vascularity of HMEC-1 Scr-siRNA or HMEC-1 F3-siRNA with and without 3 µg/mL 
mCRP was photographed. Images are representative from 3 animals for each group. 
Original magnification, 10X; scale bar 1000 mm. (F) Colorimetric determination of 
hemoglobin concentration in Matrigel plugs. Seven days after implantation, Matrigel 
plugs were removed to analyze the hemoglobin content. Bars represent the mean ± 
SEM (N=3). Statistical analysis was performed by Student's t test (***P < 0.001 vs ctrl).  
Figure 6: nCRP is dissociating into mCRP in mECs membrane. (A) Representative 
confocal images of the nCRP treated mEC cultures after 2, 4, 6 and 8 hours of 
incubation in normoxic conditions. Images show double immunofluorescence staining 
of nCRP or mCRP (green) as indicated and Hoechst dye to stain nuclei (blue). Scale 
bar: 10 µm. (B-C) Western blot analysis of (B) nCRP on supernatant and (C) mCRP in 
mEC. Data are given as mean (normalized with Ponceau staining or with β-actin) ± 
SEM. (N=3). Statistical analysis was performed by ANOVA followed by the Dunnett’s 
test (*P<0.05 vs time 0). (D)Confluent cultures of mECs were preincubated for 1 hour 
with anti-CD32 (100µg/mL) or siRNA CD32 in normoxic conditions. Then, all were 
treated with nCRP (3µg/mL) and mCRP was detected after 4 and 8 hours of incubation 
Representative confocal images of double immunofluorescence staining of mCRP 
(green) and Hoechst (blue). Scale bar: 10 µm. (E) mCRP in mECs was quantified by 
computer assisted image morphometric analysis. Data are given as mCRP positive 
area per cell (µm2/cell) ± SEM. (N=3). Statistical analysis was performed by Student’s t-
test (*P<0.05; **P<0.01 vs control). (F) mCRP formation from 4 hours to 8 hours of 
incubation  (N=3). Statistical analysis was performed by Student’s t-test (***P<0.001 vs 
control).  
 
